Related Experiment Video

Updated: Aug 19, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Recent advances in pneumococcal vaccination of children

Fiona M Russell1, E K Mulholland

  • 1Centre for International Child Health, Department of Paediatrics, University of Melbourne, Royal Children's Hospital, Parkville, Melbourne, Australia. fionarussell@connect.com.fj

Annals of Tropical Paediatrics
|February 22, 2005
PubMed

Insights

Pneumococcal conjugate vaccines (PCV) show high efficacy against invasive pneumococcal disease in children but lower efficacy against pneumonia, especially in HIV-positive infants. Affordability and wider serotype coverage are crucial for global impact.

Area of Science:

  • Pediatrics
  • Immunology
  • Epidemiology

Background:

  • Pneumococcal disease remains a significant global cause of childhood illness and death.
  • Limited epidemiological data exists on the burden of vaccine-preventable pneumococcal disease.
  • New pneumococcal conjugate vaccines (PCV) present a potential solution for infant disease prevention.

Purpose of the Study:

  • To evaluate the efficacy of pneumococcal conjugate vaccines (PCV) against various forms of pneumococcal disease in infants.
  • To assess the impact of HIV status on PCV efficacy.
  • To identify barriers to PCV introduction and suggest future research directions.

Main Methods:

  • Review of existing epidemiological data and clinical trial results on PCV efficacy.
  • Analysis of vaccine effectiveness against invasive pneumococcal disease, pneumonia, and otitis media.
  • Consideration of factors like HIV status, vaccine cost, and serotype coverage.

Main Results:

  • PCV efficacy against invasive vaccine-type pneumococcal disease in young children ranges from 77-97%.
  • Efficacy against radiological pneumonia is lower (23-30% in HIV-negative infants) and significantly reduced in HIV-positive infants (65% for invasive disease, no significant efficacy for pneumonia).
  • PCV shows modest efficacy against acute otitis media, with better prevention of recurrent or severe cases.

Conclusions:

  • While PCV is effective against invasive pneumococcal disease, its impact on pneumonia is limited, particularly in vulnerable populations.
  • High vaccine cost hinders widespread adoption, necessitating the development of more affordable vaccines with broader serotype coverage.
  • Further research into alternative vaccination strategies, including maternal/neonatal immunization and combined vaccine schedules, is warranted.

More Related Videos

Constructing Mutants in Serotype 1 Streptococcus pneumoniae strain 519/4306:06

Constructing Mutants in Serotype 1 Streptococcus pneumoniae strain 519/43

Published on: September 11, 2020

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens13:47

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Published on: May 19, 2020

Related Concept Videos

Poliomyelitis01:17

Poliomyelitis

Poliomyelitis is caused by poliovirus, a small, non-enveloped, positive-sense RNA virus of the Picornaviridae family and Enterovirus genus. Transmission occurs primarily via the fecal-oral route, often through ingestion of contaminated water or food. The virus initially replicates in the oropharynx and intestinal mucosa, particularly in lymphoid tissues such as the tonsils, Peyer’s patches, and regional lymph nodes. Primary viremia follows, allowing dissemination throughout the body.In most...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Vaccinations01:51

Vaccinations

Overview
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following: